Fatty Acid Metabolites in Rapidly Proliferating Breast Cancer

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  O'Flaherty, Joseph T ^a   Wooten, Rhonda E ^a   Samuel, Michael P ^a   Thomas, Michael J ^a   Levine, Edward A ^a   Case, L Douglas ^a   Akman, Steven A ^a   Edwards, Iris J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 13 HYDROXYOCTADECAENOATE; 15 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; 5 OXOEICOSATETRAENOATE; FATTY ACID; HYDROXY FATTY ACID; LIPOXYGENASE; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID METABOLISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MITOSIS;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FATTY ACIDS; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877021616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063076     Document Type: Article

References (44)

1. Caly M, Genin P, Ghuzlan AA, Elie C, Freneaux P, et al. (2004) Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases. Anticancer Res 24: 3283-3288.
2. Offersen BV, Alsner J, Ege Olsen K, Riisbro R, Brunner N, et al. (2008) A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol 47: 618-632.
3. Nie D, (2007) Cyclooxygenases and lipoxygenases in prostate and breast cancers. Front Biosci 12: 1574-1585.
4. Schneider C, Pozzi A, (2011) Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Rev 30: 277-294.
5. Jiang WG, Douglas-Jones A, Mansel RE, (2003) Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids 69: 275-281.
6. Jiang WG, Douglas-Jones AG, Mansel RE, (2006) Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins Leukot Essent Fatty Acids 74: 125-134.
7. Mohammad AM, Abdel HA, Abdel W, Ahmed AM, Wael T, et al. (2006) Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy. Indian J Cancer 43: 163-168.
8. Avis I, Hong SH, Martinez A, Moody T, Choi YH, et al. (2001) Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. Faseb J 15: 2007-2009.
9. Liu XH, Connolly JM, Rose DP, (1996) The 12-lipoxygenase gene-transfected MCF-7 human breast cancer cell line exhibits estrogen-independent, but estrogen and omega-6 fatty acid-stimulated proliferation in vitro, and enhanced growth in athymic nude mice. Cancer Lett 109: 223-230.
10. O'Flaherty JT, Rogers LC, Paumi CM, Hantgan RR, Thomas LR, et al. (2005) 5-Oxo-ETE analogs and the proliferation of cancer cells. Biochim Biophys Acta 1736: 228-236.
11. Tong WG, Ding XZ, Adrian TE, (2002) The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun 296: 942-948.
12. Zeeneldin AA, Mohamed AM, Abdel HA, Taha FM, Goda IA, et al. (2009) Survival effects of cyclooxygenase-2 and 12-lipooxygenase in Egyptian women with operable breast cancer. Indian J Cancer 46: 54-60.
13. Jiang WG, Watkins G, Douglas-Jones A, Mansel RE, (2006) Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids 74: 235-245.
14. Kelavkar U, Glasgow W, Eling TE, (2002) The effect of 15-lipoxygenase-1 expression on cancer cells. Curr Urol Rep 3: 207-214.
15. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G, Cohen C, (2007) COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol 15: 255-259.
16. Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C, et al. (2003) Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129: 375-382.
17. Barisik NO, Keser SH, Gul AE, Sensu S, Kandemir NO, et al. (2011) The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast. Med Oncol 28: 703-708.
18. Kelly LM, Hill AD, Kennedy S, Connolly EM, Ramanath R, et al. (2003) Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 29: 707-710.
19. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, et al. (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102: 627-637.
20. Park BW, Park S, Park HS, Koo JS, Yang WI, et al. (2012) Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes. Breast Cancer Res Treat 133: 741-751.
21. Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, et al. (2011) Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 126: 149-155.
22. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, et al. (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28: 1467-1472.
23. Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA, et al. (2011) COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 130: 657-662.
24. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA, (2011) Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf 20: 131-137.
25. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, et al. (1999) Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140: 27-35.
26. Fentiman IS, Duhig T, Griffiths AB, Taylor-Papadimitriou J, (1984) Cyclic AMP inhibits the growth of human breast cancer cells in defined medium. Mol Biol Med 2: 81-88.
27. Planchon P, Veber N, Magnien V, Prevost G, Starzec AB, et al. (1995) Evidence for separate mechanisms of antiproliferative action of indomethacin and prostaglandin on MCF-7 breast cancer cells. Life Sci 57: 1233-1240.
28. Reno F, Baj G, Surico N, Cannas M, (2004) Exogenous prostaglandin E2 inhibits TPA induced matrix metalloproteinase-9 production in MCF-7 cells. Prostaglandins Other Lipid Mediat 73: 237-247.
29. Kort WJ, Bijma AM, van Dam JJ, van der Ham AC, Hekking JM, et al. (1992) Eicosanoids in breast cancer patients before and after mastectomy. Prostaglandins Leukot Essent Fatty Acids 45: 319-327.
30. Bennett A, Stamford IF, Berstock DA, Dische F, Singh L, et al. (1989) Breast cancer, prostaglandins and patient survival. Br J Cancer 59: 268-275.
31. Fulton AM, Ownby HE, Frederick J, Brennan MJ, (1986) Relationship of tumor prostaglandin levels to early recurrence in women with primary breast cancer: clinical update. Invasion Metastasis 6: 83-94.
32. Karmali RA, Welt S, Thaler HT, Lefevre F, (1983) Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer 48: 689-696.
33. Edwards IJ, Berquin IM, Sun H, O'Flaherty JT, Daniel LW, et al. (2004) Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin. Clin Cancer Res 10: 8275-8283.
34. O'Flaherty JT, Thomas MJ, (1985) Effect of 15-lipoxygenase-derived arachidonate metabolites on human neutrophil degranulation. Prostaglandins Leukot Med 17: 199-212.
35. O'Flaherty JT, Cordes JF, Lee SL, Samuel M, Thomas MJ, (1994) Chemical and biological characterization of oxo-eicosatetraenoic acids. Biochim Biophys Acta 1201: 505-515.
36. Curran-Everett D, (2000) Multiple comparisons: philosophies and illustrations. Am J Physiol Regul Integr Comp Physiol 279: R1-8.
37. Funk CD, Powell WS, (1983) Metabolism of linoleic acid by prostaglandin endoperoxide synthase from adult and fetal blood vessels. Biochim Biophys Acta 754: 57-71.
38. Hamberg M, (1998) Stereochemistry of oxygenation of linoleic acid catalyzed by prostaglandin-endoperoxide H synthase-2. Arch Biochem Biophys 349: 376-380.
39. Kawakami Y, Nakamura T, Hosokawa T, Suzuki-Yamamoto T, Yamashita H, et al. (2009) Antiproliferative activity of guava leaf extract via inhibition of prostaglandin endoperoxide H synthase isoforms. Prostaglandins Leukot Essent Fatty Acids 80: 239-245.
40. Connolly JM, Liu XH, Rose DP, (1996) Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor. Nutr Cancer 25: 231-240.
41. Brash AR, Jisaka M, Boeglin WE, Chang MS, (1999) Molecular cloning of a second human 15S-lipoxygenase and its murine homologue, an 8S-lipoxygenase. Their relationship to other mammalian lipoxygenases. Adv Exp Med Biol 447: 29-36.
42. Kelavkar U, Lin Y, Landsittel D, Chandran U, Dhir R, (2006) The yin and yang of 15-lipoxygenase-1 and delta-desaturases: dietary omega-6 linoleic acid metabolic pathway in prostate. J Carcinog 5: 9.
43. Wecksler AT, Kenyon V, Deschamps JD, Holman TR, (2008) Substrate specificity changes for human reticulocyte and epithelial 15-lipoxygenases reveal allosteric product regulation. Biochemistry 47: 7364-7375.
44. Vangaveti V, Baune BT, Kennedy RL, (2010) Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and atherogenesis. Ther Adv Endocrinol Metab 1: 51-60.